DXNVX, Full-Scale Entry into Chinese Market... Expecting Synergy with Kori Group Network

[Asia Economy Reporter Jang Hyowon] DxVx, a biohealthcare solution company based on the microbiome, is directly entering the Chinese market by establishing a subsidiary in China.

DxVx announced on the 9th that it will establish a 100% subsidiary, "Beijing DIWEISI Biotechnology Co., Ltd.," in Beijing, China.

Through its Chinese subsidiary, DxVx plans to build its own online and offline distribution network in the Chinese market. At the same time, the industry expects synergies to be created among the local affiliated networks in China, including Beijing Hanmi Pharmaceutical, Kori China, and DxVx’s Chinese subsidiary.

Im Jong-yoon, the largest shareholder of DxVx and president of Hanmi Pharmaceutical, previously served as co-president (chairman of the board) of Beijing Hanmi Pharmaceutical, where he led the growth of Beijing Hanmi Pharmaceutical through ▲ research and development (R&D) ▲ numerous clinical trials with large hospitals ▲ expansion and diversification of sales channels, laying the foundation for stable settlement in the Chinese market.

DxVx is already supplying infant healthcare products to the Chinese market by utilizing the network established by the Kori Group in China. It has also prepared to supply various products, including in vitro diagnostic medical devices, to the Chinese market by signing a strategic MOU with Guzhou Tong, the largest pharmaceutical and medical device distribution company in China.

In particular, it is known that DxVx plans to launch and distribute its own microbiome-based healthcare brand and various functional cosmetics locally in China, which is expected to further activate its business in China.

Park Sang-tae, CEO of DxVx, stated, “By securing our own distribution network in China, we will simultaneously achieve growth and profitability in both the domestic and Chinese markets,” adding, “Through exchanges with domestic companies that require our experience and know-how in the Chinese market, we expect to serve as a gateway to China.”

This content was produced with the assistance of AI translation services.